Earnings summaries and quarterly performance for RIGEL PHARMACEUTICALS.
Executive leadership at RIGEL PHARMACEUTICALS.
Raul Rodriguez
Detailed
Chief Executive Officer
CEO
David Santos
Detailed
Executive Vice President and Chief Commercial Officer
Dean Schorno
Detailed
Executive Vice President and Chief Financial Officer
Lisa Rojkjaer
Detailed
Executive Vice President and Chief Medical Officer
Raymond Furey
Detailed
Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary
Board of directors at RIGEL PHARMACEUTICALS.
Research analysts who have asked questions during RIGEL PHARMACEUTICALS earnings calls.
Joseph Pantginis
H.C. Wainwright & Co.
4 questions for RIGL
Also covers: ARMP, BCDA, BLRX +15 more
Yigal Nochomovitz
Citigroup Inc.
3 questions for RIGL
Also covers: ALDX, APLS, ARCT +22 more
Farzin Haque
Jefferies
2 questions for RIGL
Also covers: ABEO, ARWR, AUPH +3 more
Kalpit Patel
B. Riley Securities
2 questions for RIGL
Also covers: DERM, FBRX, GERN +4 more
Amin Makarem
Jefferies
1 question for RIGL
Also covers: ABEO, CELC, CMPX
Ayan Hussein
Cantor Fitzgerald
1 question for RIGL
Also covers: XFOR
Kristen Kluska
Cantor Fitzgerald
1 question for RIGL
Also covers: ABEO, ADMA, AQST +24 more
Recent press releases and 8-K filings for RIGL.
Rigel Pharmaceuticals Reports Strong Product Sales Growth and Increased Revenue Guidance
RIGL
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals reported strong U.S. net product sales growth of 65% year-over-year to $64.1 million in Q4 2025 and $166 million through Q3 2025.
- The company increased its total revenue guidance for 2025 to $285-$290 million, with net product sales guidance of $225-$230 million.
- Key product performance includes Tavalisse sales of $44.7 million with 70% year-over-year growth, Gavreto sales growing to over $11 million per quarter, and Rezlidhia showing 50% year-over-year growth.
- Rigel achieved net income of approximately $28 million through Q3 2025 and increased its cash balance by $60 million to $137 million.
- The company is advancing its pipeline, including the IRAK1/4 inhibitor program with an upcoming oral presentation at ASH and fast-track/orphan designation, and pursuing in-licensing opportunities for differentiated hematology/oncology assets.
5 days ago
Rigel Updates on Financial Performance, Product Growth, and Pipeline at Piper Sandler Conference
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel reported $166 million in total revenue through Q3 and $64 million in Q3 alone, achieving profitability in each of the first three quarters ,.
- The company increased its full-year total revenue guidance to $285-$290 million, with net product sales guidance of $225-$230 million.
- Key products demonstrated strong growth, including Tavalisse with 70% year-over-year growth to $44.7 million, Gavreto sales exceeding $11 million per quarter, and Rezlidhia growing 50% year-over-year.
- Rigel's IRAK1/4 inhibitor program for lower risk MDS has received Fast-Track and Orphan Designation from the FDA, with new data to be presented at ASH and the dose expansion phase underway.
- The company's cash balance increased by $60 million to $137 million, providing funding for pipeline opportunities.
5 days ago
Rigel Pharmaceuticals CFO Highlights Strong Commercial Growth and Pipeline Opportunities
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel Pharmaceuticals reported US net product sales of $64 million in Q3 and $166 million cumulatively through Q3, reflecting 65% year-over-year growth.
- The company has increased its full-year guidance for total revenue to $285 million-$290 million, with net product sales projected at $225 million-$230 million and collaboration revenues at $60 million, representing 55%-59% year-over-year growth.
- Rigel's commercial products, including TAVALISSE ($44.7 million) and GAVRETO (over $11 million), are experiencing significant growth, with TAVALISSE showing 70% year-over-year growth.
- The company is advancing its pipeline with an IRAK1/4 inhibitor program in lower-risk MDS, which will have an oral presentation at ASH, and strategic collaborations for olutasidenib in various IDH1 positive indications.
- Rigel maintains a strong financial position with a cash balance of $137 million and net income of approximately $28 million through Q3.
5 days ago
Rigel Pharmaceuticals Updates on Strong Commercial Growth, Profitability, and Pipeline Progress at Jefferies Conference
RIGL
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals reported strong financial performance, achieving profitability in 2024 and through the first three quarters of 2025, generating $60 million in cash year-to-date.
- Net product sales for the last quarter reached $64 million, marking a 65% increase year-over-year, with significant contributions from TAVALISSE, REZLIDHIA, and GAVRETO.
- The company raised its full-year 2025 guidance, projecting total revenue between $285-$290 million and net product sales of $225-$230 million, while reaffirming its expectation for net income positive results.
- Rigel's pipeline includes R289, an IRAK1/4 inhibitor for low-risk MDS, with new data to be presented at the upcoming ASH meeting and a registration study targeted for 2027.
- The strategic focus involves continued commercial expansion, in-licensing additional late-stage hematology and oncology assets, and funding transformational pipeline programs with internally generated cash.
Nov 18, 2025, 10:00 AM
Rigel Pharmaceuticals Highlights Profitability, Strong Commercial Growth, and Pipeline Development
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel Pharmaceuticals, a hematology and oncology biotech company, has achieved profitability and generated $60 million in cash this year thus far, with plans to invest this cash into transformational pipeline programs.
- The company reported $64 million in net product sales last quarter, representing a 65% increase from the same quarter a year earlier, driven by strong performance from TAVALISSE, GAVRETO, and REZLIDHIA.
- Rigel has raised its full-year revenue guidance to $285-$290 million, including $225-$230 million in net product sales, and anticipates 55-59% growth for the year.
- Key pipeline assets include R289 for low-risk MDS, with a registration study planned for 2027, and Olutasidenib (REZLIDHIA) being explored in various new indications and collaborations.
Nov 18, 2025, 10:00 AM
Rigel Pharmaceuticals Reports Strong Commercial Growth and Raised Guidance
RIGL
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Rigel Pharmaceuticals reported $64 million in net product sales last quarter, marking a 65% increase from the prior year, with year-to-date net product sales reaching $166 million.
- The company is profitable, having generated $60 million in cash year-to-date, and reported a net income of $27.9 million last quarter.
- Rigel raised its full-year revenue guidance to $285 million-$290 million, with $225 million-$230 million expected from net product sales, and reiterated its guidance for being net income positive for the year.
- Key pipeline asset R289 for low-risk MDS will have new data presented at ASH, with a registration study planned for 2027. The company also plans to in-license one or two additional molecules in the next few years to expand its commercial portfolio.
Nov 18, 2025, 10:00 AM
Rigel Pharmaceuticals Announces Publication of Final 5-Year REZLIDHIA Data and Collaboration Updates
RIGL
Product Launch
New Projects/Investments
- Rigel Pharmaceuticals announced the publication of final five-year data from the pivotal Phase 2 registrational trial evaluating REZLIDHIA (olutasidenib) for the treatment of patients with relapsed or refractory (R/R) mutant isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AML).
- The published data demonstrated durable efficacy and a manageable safety profile for olutasidenib, including in patients previously treated with venetoclax-based regimens, with no new safety signals identified over five years.
- In 147 efficacy evaluable patients, 35% achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with a median duration of CR/CRh of 25.3 months. The overall response rate (ORR) was 48%, and the median overall survival (OS) was 11.5 months.
- Rigel is also advancing strategic collaborations, including the activation of a fifth study with MD Anderson and the enrollment of the first patient in the CONNECT TarGeT-D study, to further evaluate olutasidenib in other IDH1-mutated myeloid malignancies and high-grade glioma.
Nov 17, 2025, 1:05 PM
Rigel Pharmaceuticals Reports Strong Q3 2025 Financial Results and Raises Full-Year Guidance
RIGL
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Rigel Pharmaceuticals reported total revenue of $69.5 million and record net product sales of $64.1 million for the third quarter of 2025, marking a 65% year-over-year increase in net product sales. The company also achieved net income of $27.9 million and ended the quarter with a cash balance of $137.1 million.
- Based on strong performance, Rigel raised its full-year 2025 total revenue guidance to $285-$290 million and net product sales guidance to $225-$230 million, anticipating 55%-59% growth compared to 2024.
- All three commercial products demonstrated significant year-over-year growth in Q3 2025: TAVALISSE net product sales grew 70% to $44.7 million, GAVRETO grew 56% to $11.1 million, and REZLIDHIA grew 50% to $8.3 million.
- The company is advancing its pipeline, with the R289 study in lower-risk MDS completing dose escalation enrollment and beginning dose expansion, with updated data to be presented at the ASH annual meeting. Olutasidenib is also progressing through strategic collaborations for IDH1-mutated AML and glioma.
Nov 4, 2025, 9:30 PM
Rigel Raises 2025 Financial Guidance Following Strong Q3 2025 Performance
RIGL
Earnings
Guidance Update
New Projects/Investments
- Rigel reported Q3 2025 Net Portfolio Sales of $64.1 million, marking a 65% increase compared to Q3 2024.
- The company raised its 2025 net product sales guidance to $225 million – $230 million (from $210 million – $220 million) and total revenue guidance to $285 million – $290 million (from $270 million – $280 million).
- Rigel anticipates achieving positive net income for the full year 2025.
- Development programs are advancing, including the R289 Phase 1b study in lower-risk MDS, which has received Fast Track and Orphan Drug designations, and the expansion of olutasidenib through strategic collaborations for various hematologic and oncology indications.
Nov 4, 2025, 9:30 PM
Rigel Pharmaceuticals Reports Strong Q3 2025 Results and Raises Full-Year Guidance
RIGL
Earnings
Guidance Update
New Projects/Investments
- Rigel Pharmaceuticals reported Q3 2025 total revenue of $69.5 million, including $64.1 million in net product sales, and a net income of $27.9 million.
- For the nine months ended September 30, 2025, total revenues reached $224.5 million, resulting in a net income of $99.0 million.
- The company raised its full-year 2025 total revenue guidance to approximately $285 to $290 million and net product sales guidance to $225 to $230 million, anticipating positive net income for the full year.
- Rigel completed enrollment in the dose escalation phase and initiated the dose expansion phase of the Phase 1b study for R289 in lower-risk MDS, with updated data to be presented at ASH in December.
Nov 4, 2025, 9:11 PM
Quarterly earnings call transcripts for RIGEL PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more